Wall Street analyst estimates for Lucyd, Inc (LUCY): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Lucyd, Inc develops and sells smart eyewear in North America. It offers smart eyewear products to enable wearer to listen to music, take and make calls, and use voice assistants and ChatGPT to perform smartphone tasks hands-free, as well as prescription eyeglasses, ready-to-wear sunglasses, safety glasses, and sport glasses under the Lucyd Lyte, Lucyd Armor, Nautica, Eddie Bauer, and Reebok brand names.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.35 | ||
| 2026-08-14 | $-0.26 | $-0.37 | +29.7% |
| 2026-05-14 | $-0.37 | $-0.47 | +21.3% |
| 2026-03-25 | $-0.28 | $-0.43 | +34.9% |
| 2025-11-13 | $-0.38 | $-0.49 | +22.4% |
| 2025-08-14 | $-0.66 | $-0.77 | +14.3% |
| 2025-05-13 | $-0.72 | $-0.73 | +1.4% |
| 2025-03-24 | $-0.41 | $-1.22 | +66.4% |
Valuation Ratios
| Price / Book | 0.77 |
| EV / EBITDA | -0.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $4821 | $56997 | $690670 | $659788 | $1.2M | $1.6M | $2.7M |
| Cost of Revenue | $7735 | $74266 | $542416 | $716077 | $1.3M | $1.4M | $2.1M |
| Gross Profit | -$2914 | -$17269 | $148254 | -$56289 | -$119329 | $215190 | $567451 |
| Research & Development | $4083 | $36894 | $86261 | $524692 | $662184 | $819387 | $725.4M |
| Selling, General & Admin | $46322 | $468846 | $3.2M | $4.9M | $5.9M | $7.2M | $2.25B |
| Operating Expenses | $106513 | $635740 | $3.4M | $5.5M | $6.7M | $8.1M | $9.1M |
| Operating Income | -$109427 | -$653009 | -$3.2M | -$5.6M | -$6.9M | -$7.9M | -$8.5M |
| EBITDA | -$109427 | -$762224 | -$3.2M | -$5.5M | -$6.6M | -$7.6M | -$7.5M |
| Interest Expense | 0 | $4966 | $39433 | $105171 | $3036 | 0 | 0 |
| Pre-tax Income | -$109427 | -$768184 | -$3.2M | -$5.7M | -$6.7M | -$7.8M | -$7.6M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$109427 | -$768184 | -$3.2M | -$5.7M | -$6.7M | -$7.8M | -$7.6M |
| EPS | $-2.64 | $-5.19 | $-12.37 | $-17.41 | $-12.67 | $-5.19 | $-1.90 |
| EPS (Diluted) | $-2.64 | $-5.19 | $-12.37 | $-17.41 | $-12.67 | $-5.19 | $-1.90 |
| Shares Outstanding (Diluted) | $99448 | $148014 | $262281 | $326448 | $525800 | $1.5M | $4.0M |
Price
| Price | $0.86 |
| Market Cap | $5M |
| Exchange | NASDAQ |
| Country | US |
Related companies: APRE · BCDA · BMRA · CELZ · CHEK · KPRX · MHUA
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of LUCY: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks